FUSION PROTEIN HAVING ENHANCED IN VIVO ERYTHROPOIETIN ACTIVITY

摘要

PURPOSE: A fusion protein having enhanced in vivo erythropoietin activity is provided. Therefore, it increases the half-life of erythropoietin in vivo significantly by increasing the content of a sugar chain with maintaining erythropoietin activity, while it does not induce antigenicity when applied to a living body. CONSTITUTION: The fusion protein having enhanced in vivo erythropoietin activity is prepared by fusion of the carboxy terminal of human erythropoietin and the carboxy terminal peptide(CTP) of human chorionic gonadotropin(HCG) beta subunit, in which the carboxy terminal peptide comprises 112th to 145th amino acids, preferably 118th to 145th amino acids of HCG beta subunit represented by the amino acid sequence of SEQ ID NO: 1 or a portion thereof.